[Fetal/neonatal allo-immune thrombocytopenias: the unsolved questions].
The allo-immune thrombocytopenias are the major cause of severe thrombocytopenia in the fetus and the neonate. The frequency of this affection has been evaluated to be 1 out of 800 to 1000 live births. The deleterious consequences of severe thrombocytopenia are intracranial hemorrhages leading to death or neurological sequelae. Progress in platelet immunology and antenatal medicine has allowed a better diagnosis of this affection and development of the antenatal management of high-risk pregnancies. Nevertheless there are unsolved questions, particularly concerning the mechanism of the maternal immunization, the laboratory difficulties for the identification of the alloantibodies, the absence of antenatal management standardization.
Kaplan
C
C
Laboratoire d'immunologie plaquettaire, INTS, 6, Paris, France. ckaplan@ints.fr
D000328:Adult; D016824:Antigens, Human Platelet / Q000276:immunology; D001792:Blood Platelets / Q000276:immunology*; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis / Q000209:etiology / Q000276:immunology; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007114:Immunization; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007231:Infant, Newborn; D007518:Isoantibodies / Q000276:immunology*; D017713:Platelet Transfusion; D011247:Pregnancy; D018566:Pregnancy, High-Risk; D011295:Prenatal Care; D013921:Thrombocytopenia / Q000151:congenital / Q000175:diagnosis / Q000196:embryology / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy
D016824:Antigens, Human Platelet; D016756:Immunoglobulins, Intravenous; D007518:Isoantibodies